Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 12/20 | 0.53 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671219 | 0.87 | APLNR (0.51) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL29671186 | 0.86 | APLNR (0.50) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL29671340 | 0.83 | APLNR (0.61) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL29671236 | 0.81 | TAS2R14 (0.53) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL29671252 | 0.80 | APLNR (0.49) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL29665769 | 0.80 | APLNR (0.49) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL22909373 | 0.79 | AR (0.45) | HDAC11HDAC8HDAC6BCHE | |
| SCHEMBL29671208 | 0.78 | APLNR (0.47) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL27020701 | 0.77 | AR (0.43) | — | |
| SCHEMBL29665682 | 0.77 | APLNR (0.54) | TAS2R14CXCR3PTGESTAS2R8CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | TAS2R14 2580/4885CXCR3 1091/4885PTGES 4580/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | TAS2R14 3794/4885CXCR3 4336/4885PTGES 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.